China’s Tasly to list biotech arm in $1 billion Hong Kong IPO: sources

HONG KONG (Reuters) РChina’s Tasly Pharmaceutical Group is planning to list its biopharma unit in Hong Kong to raise about $1 billion, in what is likely to be the largest biotech float in the city this year, people with knowledge of the matter said.
( read original story …)